Simulations Plus (NasdaqGS:SLP) FY Conference Transcript

Summary of Simulations Plus FY Conference Call Company Overview - Company: Simulations Plus (NasdaqGS:SLP) - Industry: Biosimulation and Drug Development Key Points Differentiating Features of Simulations Plus Platform - Simulations Plus offers several biosimulation solutions, including ADMET Predictor, GastroPlus, Monolix, and Pro-ficiency, characterized by their ease of use and scientific functionality [4][5][6] - The company emphasizes the accuracy of its predictive outputs, particularly in the discovery space, where ADMET Predictor consistently outperforms competitors [5] - Monolix is noted as the highest growth software platform due to its workflow orientation and integration capabilities [6] Customer Segmentation and Revenue Mix - The customer base is approximately 75% large pharma and 25% biotech, with revenues driven 80% from clinical applications and 20% from discovery [8][9] - The company anticipates a consistent revenue mix of 60-65% from software and 35-40% from services, with a long-term goal to increase software revenue to 70% [16][17] Financial Guidance and Growth Expectations - For FY 2026, the company has set a conservative growth guidance of 0%-4%, reflecting a cautious outlook based on previous year comparisons [10][14] - The first quarter showed overperformance in service business, with a backlog at two-year highs, indicating potential for growth in the latter half of the fiscal year [11][12] Strategic Initiatives and Product Development - The company is focusing on maximizing existing products while also developing a new product roadmap that integrates AI capabilities into their biosimulation ecosystem [22][23] - The integration of AI is expected to enhance productivity and efficiency, potentially allowing for new pricing models and revenue streams [30][31] Regulatory Environment and Market Trends - The FDA's push for alternative methodologies is seen as a long-term opportunity, with expectations for meaningful adoption and revenue impact within 2-3 years [35][40] - Simulations Plus is well-positioned to leverage its tools, such as GastroPlus and QSP capabilities, to meet evolving regulatory requirements and reduce reliance on animal testing [38][39] Competitive Landscape and Market Position - The company views AI as a tool that enhances its existing capabilities rather than a direct competitor, with many AI startups becoming clients rather than replacing Simulations Plus' offerings [48][49] - The historical context of AI adoption in drug development suggests that the company will continue to play a significant role in the biosimulation market [49] Additional Insights - The company is reorganizing its sales strategy to focus on cross-selling its full suite of platforms, which is expected to drive growth [20][21] - There is a recognition of the importance of data management and integration as pharma companies invest in AI, which aligns with Simulations Plus' product development strategy [43][44] This summary encapsulates the key insights from the conference call, highlighting the company's strategic direction, market positioning, and growth expectations in the biosimulation industry.